SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?


To: Biotech Jim who wrote (10734)4/25/2016 10:10:24 AM
From: Robohogs  Read Replies (1) | Respond to of 12215
 
New VWAP Chart for XBI - Yahoo Finance had split wrong and volume looked adjusted - still not quite sure.



And Sentiment from Stocktwits (whose data seems to change btw) is staying high but not extreme. No reason to update chart here as nothing new becoming apparent - will by end of week. The historical data on Stocktwits is changing though. I go every couple of days and scroll over chart starting with last piece of data with a date and move forward adjusting my data as needed. I could go even further back but that is absurd - all of the data does subtly move though.



To: Biotech Jim who wrote (10734)4/27/2016 12:00:07 PM
From: tuck  Read Replies (1) | Respond to of 12215
 
CARA: I am still fishing for my first tranche since the pop on drop on news of the hold being lifted. And the pullback has been so hard, that I keep thinking I missed something obvious in the PR. Something that figures for a more negative outcome on the safety/efficacy/marketability spectrum than investors hoped when the trial was started. It does seem overly punished for a mere loss of three months time.

Anyone got a comment on that?

Cheers, Tuck



To: Biotech Jim who wrote (10734)4/28/2016 10:26:36 AM
From: Biotech Jim  Read Replies (1) | Respond to of 12215
 
Third tranche of CARA obtained this morning, under $6. Now time to rise.

As to the post op pain trial put on clinical hold, there were 4 pts showing mild hypernatremia (>150 mmol/L) of which 2 were protocol violations. For future dosings, keep in mind the dosing interval vs earlier work. The 4 hypernatremia patients displayed highs of Na+ at 154, 151, 151 and 150.